These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

405 related items for PubMed ID: 19008049

  • 1. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
    Nielsen DL, Andersson M, Kamby C.
    Cancer Treat Rev; 2009 Apr; 35(2):121-36. PubMed ID: 19008049
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. An overview of HER-targeted therapy with lapatinib in breast cancer.
    McArthur H.
    Adv Ther; 2009 Mar; 26(3):263-71. PubMed ID: 19365626
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
    Cameron DA, Stein S.
    Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
    [Abstract] [Full Text] [Related]

  • 6. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
    Reid A, Vidal L, Shaw H, de Bono J.
    Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
    Nielsen DL, Kümler I, Palshof JA, Andersson M.
    Breast; 2013 Feb; 22(1):1-12. PubMed ID: 23084121
    [Abstract] [Full Text] [Related]

  • 8. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R, O'Regan RM.
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [Abstract] [Full Text] [Related]

  • 9. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
    Halterman PA.
    Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
    [Abstract] [Full Text] [Related]

  • 10. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
    Conte P, Guarneri V, Bengala C.
    Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
    [Abstract] [Full Text] [Related]

  • 11. Dual HER2-targeted approaches in HER2-positive breast cancer.
    Ahn ER, Vogel CL.
    Breast Cancer Res Treat; 2012 Jan; 131(2):371-83. PubMed ID: 21956210
    [Abstract] [Full Text] [Related]

  • 12. Target-based therapies in breast cancer: current status and future perspectives.
    Normanno N, Morabito A, De Luca A, Piccirillo MC, Gallo M, Maiello MR, Perrone F.
    Endocr Relat Cancer; 2009 Sep; 16(3):675-702. PubMed ID: 19525314
    [Abstract] [Full Text] [Related]

  • 13. Advances in adjuvant therapy for breast cancer.
    Slamon DJ, Romond EH, Perez EA, CME Consultants, Inc.
    Clin Adv Hematol Oncol; 2006 Mar; 4(3 Suppl 7):suppl 1, 4-9; discussion suppl 10; quiz 2 p following suppl 10. PubMed ID: 16736568
    [Abstract] [Full Text] [Related]

  • 14. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
    Chen FL, Xia W, Spector NL.
    Clin Cancer Res; 2008 Nov 01; 14(21):6730-4. PubMed ID: 18980964
    [Abstract] [Full Text] [Related]

  • 15. Current and future anti-HER2 therapy in breast cancer.
    Vrbic S, Pejcic I, Filipovic S, Kocic B, Vrbic M.
    J BUON; 2013 Nov 01; 18(1):4-16. PubMed ID: 23613383
    [Abstract] [Full Text] [Related]

  • 16. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors.
    Nelson MH, Dolder CR.
    Ann Pharmacother; 2006 Feb 01; 40(2):261-9. PubMed ID: 16418322
    [Abstract] [Full Text] [Related]

  • 17. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
    Sachdev JC, Jahanzeb M.
    Clin Breast Cancer; 2012 Feb 01; 12(1):19-29. PubMed ID: 21903480
    [Abstract] [Full Text] [Related]

  • 18. Issues and controversies in the treatment of HER2 positive metastatic breast cancer.
    Amar S, Moreno-Aspitia A, Perez EA.
    Breast Cancer Res Treat; 2008 May 01; 109(1):1-7. PubMed ID: 17653858
    [Abstract] [Full Text] [Related]

  • 19. Lapatinib and breast cancer: current indications and outlook for the future.
    Moreira C, Kaklamani V.
    Expert Rev Anticancer Ther; 2010 Aug 01; 10(8):1171-82. PubMed ID: 20735304
    [Abstract] [Full Text] [Related]

  • 20. Closing remarks and treatment guidelines.
    Piccart M.
    Eur J Cancer; 2001 Jan 01; 37 Suppl 1():30-33. PubMed ID: 11342198
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.